Fig. 8From: A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancerTherapeutic response evaluation with the SRGs-related prognostic signature. A–F Drug sensitivity (IC50) of bortezomib (A), cisplatin (B), docetaxel (C), gemcitabine (D), paclitaxel (E), pazopanib (F), lapatinib (G), methotrexate (H), temsirolimus (I), MK2206 (J), SB590885 (K), and VX702 (L) in the high- (red) and low-risk groups (blue)Back to article page